Physician Assistant Program year 2023 Reported 2021–2023 Source: CMS Open Payments, 2026 publication

Stacie Gilroy

Physician Assistant Papillion, NE Physician Assistant

NPI 1619906864 CMS profile 11209591

249 Olson Drive, Suite 111, Papillion, NE 68046

Open in the dashboard

General payments

$4,855

315 records reported · program years 2021–2023

Research payments

$0

Paid to them · None reported · program years 2021–2023

Ownership & investment interest

$0

None reported

Through program year 2023, Stacie Gilroy of Papillion, NE is reported in the CMS Open Payments database as having received $4,855 across 315 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 91st percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

3 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $1,523 105
2022 General $1,684 102
2021 General $1,648 108

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Stacie Gilroy
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Stacie Gilroy were reported at $0. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Stacie Gilroy Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $1,648 $132 $37–$438 $132
2022 $1,684 $155 $48–$522 $149
2023 $1,523 $167 $52–$557 $160
2024 $0 $178 $55–$600 $164
2025 $0 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2023
  1. AbbVie, Inc. $604 46 payments
  2. Lilly USA, LLC $427 34 payments
  3. Bayer HealthCare Pharmaceuticals Inc. $410 26 payments
  4. AstraZeneca Pharmaceuticals LP $386 20 payments
  5. Novo Nordisk Inc $319 24 payments
  6. Otsuka America Pharmaceutical, Inc. $242 14 payments
  7. Janssen Pharmaceuticals, Inc $208 13 payments
  8. Kowa Pharmaceuticals America, Inc. $173 12 payments
  9. Biohaven Pharmaceutical Holding Company Ltd. $168 12 payments
  10. Grifols USA, LLC $121 7 payments
  11. Other $1,797 107 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2023
  1. Food and Beverage $4,855 315 payments
Products named General payments · program years 2021–2023
  1. Kerendia $410 26 payments
  2. Ozempic $277 21 payments
  3. RYBELSUS $277 21 payments
  4. REXULTI $242 14 payments
  5. UBRELVY $235 19 payments
  6. NURTEC ODT $213 14 payments
  7. FARXIGA $201 10 payments
  8. BREZTRI $199 7 payments
  9. JARDIANCE $198 14 payments
  10. Livalo $173 12 payments
  11. Other $3,679 238 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 53 drugs

Part D claims

1,838

Median for Physician Assistant: 241

Drug cost

$120,000

Median for Physician Assistant: $4,110

Branded share of claims

12.1%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 38 $41,677
Farxiga Dapagliflozin Propanediol Brand 28 $26,315
Mounjaro Tirzepatide Brand 12 $15,526
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 18 $12,984
Myrbetriq Mirabegron Brand 15 $7,716
Atorvastatin Calcium Generic 232 $1,756
Losartan Potassium Generic 121 $1,203
Omeprazole Generic 65 $1,035
Zolpidem Tartrate Generic 34 $679
Levothyroxine Sodium Generic 103 $652

The 10 drugs with the highest cost, of 53 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 30 billing codes

Paid by Medicare

$33,882

Medicare's payments for the services billed

Medicare patients

212

Average age 74

Services billed

684

159 women, 53 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 63%
Arthritis 43%
Diabetes 30%
Chronic kidney disease 23%
Ischemic heart disease 22%
Osteoporosis 16%
Atrial fibrillation 12%
Depression 12%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

315 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Nebraska

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record